eBulletin Newsletter
NCCN Flash Updates: NCCN Templates Updated for Hodgkin Lymphoma
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Hodgkin Lymphoma to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin Lymphoma v2.2023.
- The following New NCCN Templates® have been published:
- HDL69 - ICE (Ifosfamide/CARBOplatin/Etoposide) + Nivolumab
- HDL72 - RiTUXimab and Hyaluronidase Human
- The Title has been updated on the following templates:
- HDL56 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Age >60 years
- HDL57 - AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Age >60 years
- HDL58 - CHOP (Cyclophosphamide/DOXOrubicin/VinCRIStine/PredniSONE) – Age >60 years
- HDL61 - Brentuximab vedotin + Dacarbazine – Age >60 years
- HDL64 - Brentuximab vedotin followed by AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Age >60 years
- Changes to the Indication section have been made on the following templates:
- HDL1 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage I-II Favorable
- HDL2 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage I-II Unfavorable
- HDL6 - Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine) – Stage III-IV
- HDL7- AVD (DOXOrubicin/VinBLAStine/Dacarbazine)
- HDL11 - Mini-BEAM (Carmustine/Etoposide/Cytarabine/Melphalan)
- HDL12 - MINE (Mesna/Ifosfamide/MitoXANTRONE/Etoposide)
- HDL25 - C-MOPP – Schema I (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
- HDL26 - C-MOPP – Schema II (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
- HDL31 - Brentuximab vedotin
- HDL32 - Bendamustine
- HDL46 - Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine) – Stage I-II
- HDL47 - Everolimus
- HDL48 - Lenalidomide
- HDL54 - Nivolumab
- HDL55 - Pembrolizumab
- HDL62 - Bendamustine/CARBOplatin/Etoposide
- HDL63 - GEMOX (Gemcitabine/OXALIplatin)
- HDL67 - GCD (Gemcitabine/CISplatin/Dexamethasone)
- Changes to the Reference section have been made on the following templates:
- HDL19 - CHOP (Cyclophosphamide/DOXOrubicin/VinCRIStine/PredniSONE) + RiTUXimab
- HDL31 - Brentuximab vedotin
- HDL34 - ICE (Ifosfamide/CARBOplatin/Etoposide) + RiTUXimab
- HDL50 - Brentuximab vedotin + AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Stage III-IV
- HDL54 - Nivolumab
- HDL68 - CVbP (Cyclophosphamide/VinBLAStine/PrednisoLONE) + RiTUXimab
- Changes to the Chemotherapy Regimen section have been made on the following templates:
- HDL1 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage I-II Favorable
- HDL2 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage I-II Unfavorable
- HDL3 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Stage III-IV
- HDL6 - Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine) – Stage III-IV
- HDL7 - AVD (DOXOrubicin/VinBLAStine/Dacarbazine)
- HDL11 - Mini-BEAM (Carmustine/Etoposide/Cytarabine/Melphalan)
- HDL17 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) + RiTUXimab
- HDL19 - CHOP (Cyclophosphamide/DOXOrubicin/VinCRIStine/PredniSONE) + RiTUXimab
- HDL25 - C-MOPP – Schema I (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
- HDL26 - C-MOPP – Schema II (Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine)
- HDL31 - Brentuximab vedotin
- HDL34 - ICE (Ifosfamide/CARBOplatin/Etoposide) + RiTUXimab
- HDL35 - DHAP (Dexamethasone/Cytarabine/CISplatin) + RiTUXimab
- HDL41 - IGEV (Ifosfamide/Gemcitabine/VinORELBine/PredniSONE) + RiTUXimab
- HDL46 - Escalated-dose BEACOPP (Bleomycin/Etoposide/DOXOrubicin/Cyclophosphamide/VinCRIStine/PredniSONE/Procarbazine) – Stage I-II
- HDL49 - RiTUXimab
- HDL50 - Brentuximab vedotin + AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Stage III-IV
- HDL52 - Brentuximab vedotin + Bendamustine
- HDL54 – Nivolumab
- HDL55 – Pembrolizumab
- HDL56 - ABVD (DOXOrubicin/Bleomycin/VinBLAStine/Dacarbazine) – Age >60 years
- HDL61 - Brentuximab vedotin + Dacarbazine – Age >60 years
- HDL64 - Brentuximab vedotin followed by AVD (DOXOrubicin/VinBLAStine/Dacarbazine) – Age >60 years
- HDL65 - Bendamustine + RiTUXimab
- HDL66 - GVD (Gemcitabine/VinORELBine/Liposomal DOXOrubicin) + Pembrolizumab
- HDL68 - CVbP (Cyclophosphamide/VinBLAStine/PrednisoLONE) + RiTUXimab
- Changes to the Emetic Risk section have been made on the following templates:
- HDL68 - CVbP (Cyclophosphamide/VinBLAStine/PrednisoLONE) + RiTUXimab
- Changes to the Febrile Neutropenia Risk section have been updated on the following templates:
- HDL61 - Brentuximab vedotin + Dacarbazine – Age >60 years
- Drug information notes in the Other supportive Therapy section have been updated for the following agents:
- Cytarabine
- Melphalan
- Nivolumab
- Pembrolizumab
- PrednisoLONE
- Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
- Bendamustine
- Carmustine
- CISplatin
- DOXOrubicin
- Gemcitabine
- MitoXANTRONE
- Nivolumab
- OXALIplatin
- Pembrolizumab
- Procarbazine
- VinBLAStine
- VinCRIStine
- VinORELBbine
NCCN has published updates to the following NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™:
- Prostate Cancer, Version 1.2023
- Hepatobiliary Cancer, Version 3.2022
- Pediatric Acute Lymphoblastic Leukemia, Version 1.2023
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.